Cardiac safety of ophthalmic timolol-Reference-Cited by-同舟云学术

Cardiac safety of ophthalmic timolol

Published:2016-08-31 Issue:11 Volume:15 Page:1549-1561
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Mäenpää Jukka¹,Pelkonen Olavi²

Affiliation:

1. AstraZeneca, Research and Development, Patient Safety, Respiratory, Inflammation, Autoimmunity, Infections and Vaccines Therapeutic Area, Gothenburg, Sweden

2. Department of Pharmacology and Toxicology, Institute of Biomedicine, University of Oulu, Oulu, Finland

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2016.1225718

Reference93 articles.

1. Glaucoma

2. Pharmacotherapy of Glaucoma

3. Cardiovascular drug class specificity: β-blockers

4. Management of Infantile Hemangiomas

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design and Evaluation of Ophthalmic Thermosensitive In Situ Gel of Compound Salvia;AAPS PharmSciTech;2024-08-20

2. Hollow microneedles for ocular drug delivery;Journal of Controlled Release;2024-07

3. The Effect of β-Blocker Eye Drops on Pulse Rate, Ocular Blood Flow, and Glaucoma Progression: A Retrospective Longitudinal Study;Advances in Therapy;2024-01-02

4. The molecular aspect of anti-glaucomatous eye drops - are we harming our patients?;Molecular Aspects of Medicine;2023-10

5. Severe systemic adverse reactions to ophthalmic timolol in a CYP2D6 homozygous *4 allele carrier: a case report;Pharmacogenomics;2023-09-15